Search results for "structure-activity relationship"

showing 10 items of 743 documents

Biochemical approach on the conservation of drug molecules during hair fiber formation

1997

A biochemical concept for the endogenous incorporation of drug molecules into growing hair is presented. It is based on the principles of transport across biomembranes, on the principles of biotransformation and drug melanin affinity. The approach gives explanations for current observations in hair analysis, which up to date have not been understood sufficiently. Phenomena such as the ratio of parent drug to metabolite in hair, the dependence of incorporation on the physico-chemical properties of the drug, the independence of drug incorporation on active melanogenesis (incorporation into non-pigmented hair) as well as the dependence of drug content on hair pigmentation are elucidated.

DrugCell Membrane PermeabilityMembrane permeabilitymedia_common.quotation_subjectMetaboliteBiologyAbsorptionPathology and Forensic MedicineMelaninStructure-Activity Relationshipchemistry.chemical_compoundBiotransformationKeratinotorhinolaryngologic diseasesmedicineAnimalsHumansDrug InteractionsBiotransformationmedia_commonMelaninschemistry.chemical_classificationintegumentary systemPigmentationHair analysisHair folliclemedicine.anatomical_structurePharmaceutical PreparationschemistryBiochemistrysense organsLawBiomarkersHairForensic Science International
researchProduct

Modeling caspase-1 inhibition: Implications for catalytic mechanism and drug design.

2019

Abstract The metabolic product of caspase-1, IL-1β, is an important mediator in inflammation and pyroptosis cell death process. Alzheimer's disease, septic shock and rheumatoid arthritis are IL-1β mediated diseases, making the caspase-1 an interesting target of pharmacological value. Many inhibitors have been developed until now, most of them are peptidomimetic with improved potency. In the present study, all-atom molecular dynamics simulations and the MM/GBSA method were employed to reproduce and interpret the results obtained by in vitro experiments for a series of inhibitors. The analysis shows that the tautomeric state of the catalytic His237 impact significantly the performance of the …

DrugModels MolecularPeptidomimeticmedia_common.quotation_subjectCaspase 1InflammationLigands01 natural sciences03 medical and health sciencesStructure-Activity RelationshipViral ProteinsMediatorDrug DiscoverymedicinePotencyHumansSerpins030304 developmental biologymedia_commonPharmacology0303 health sciencesDose-Response Relationship DrugMolecular Structure010405 organic chemistryChemistryMechanism (biology)Organic ChemistryCaspase 1PyroptosisGeneral Medicine0104 chemical sciencesBiochemistryDrug DesignBiocatalysisThermodynamicsmedicine.symptomEuropean journal of medicinal chemistry
researchProduct

Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities

2014

Abstract Six structurally diverse cytotoxic gold compounds are reported to cause profound and differential inhibition of the three main catalytic activities of purified 20S proteasome whilst auranofin , an established gold(I) drug in clinical use, is nearly ineffective. In particular, the gold(I) complex [( pbiH ) Au ( PPh 3 )] PF 6 , turns out to be the most potent inhibitor of all three enzyme activities with sub-micromolar IC 50 values. The present results further support the view that proteasome inhibition may play a major – yet not exclusive – role in the cytotoxic actions of gold based anticancer agents.

DrugProteasome Endopeptidase ComplexAuranofinmedia_common.quotation_subjectAntineoplastic AgentsPharmacologyBiochemistry20s proteasomeProteasome Gold compounds Anticancer drugs Enzyme inhibitionCatalysisInorganic ChemistryInhibitory Concentration 50Structure-Activity RelationshipGold CompoundsCoordination ComplexesAuranofinmedicineHumansCytotoxic T cellmedia_commonchemistry.chemical_classificationCytotoxinsChemistryEnzymeProteasomeBiochemistryBiocatalysisOrganogold CompoundsProteasome Inhibitorsmedicine.drug
researchProduct

Biopartitioning micellar separation methods: modelling drug absorption

2003

The search for new pharmacologically active compounds in drug discovery programmes often neglects biopharmaceutical properties as drug absorption. As a result, poor biopharmaceutical characteristics constitute a major reason for the low success rate for candidates in clinical development. Since the cost of drug development is many times larger than the cost of drug discovery, predictive methodologies aiding the selection of bioavailable drug candidates are of profound significance. This paper has been focussed on recent developments and applications of chromatographic systems, particularly those systems based on amphiphilic structures, in the frame of alternative approaches for estimating t…

DrugQuantitative structure–activity relationshipCell Membrane PermeabilityChromatographyChemistryDrug discoverymedia_common.quotation_subjectClinical BiochemistryQuantitative Structure-Activity RelationshipCell BiologyGeneral MedicineHealth economyBiochemistryAnalytical ChemistryPassive permeabilityBiopharmaceuticalDrug developmentSeparation methodPharmacokineticsMicellesmedia_commonJournal of Chromatography B
researchProduct

Inhibitory activities of short linear motifs underlie Hox interactome specificity in vivo

2015

Hox proteins are well-established developmental regulators that coordinate cell fate and morphogenesis throughout embryogenesis. In contrast, our knowledge of their specific molecular modes of action is limited to the interaction with few cofactors. Here, we show that Hox proteins are able to interact with a wide range of transcription factors in the live Drosophila embryo. In this context, specificity relies on a versatile usage of conserved short linear motifs (SLiMs), which, surprisingly, often restrains the interaction potential of Hox proteins. This novel buffering activity of SLiMs was observed in different tissues and found in Hox proteins from cnidarian to mouse species. Although th…

Embryo Nonmammalian[SDV]Life Sciences [q-bio]Amino Acid MotifsinteractomeInteractomeBimolecular fluorescence complementationMiceTARGET GENEDrosophila ProteinsCELL REGULATIONProtein Interaction MapsBiology (General)Hox genetranscription factorGeneticsD. melanogasterGeneral NeuroscienceQRINTERACTION MODULESGeneral MedicineREGIONSHoxTRANSCRIPTION FACTORSDrosophila melanogasterGenomics and Evolutionary BiologyOrgan Specificityembryonic structuresMedicineOligopeptidesProtein BindingResearch Articleanimal structuresQH301-705.5ScienceembryoContext (language use)Computational biology[SDV.BC]Life Sciences [q-bio]/Cellular BiologyCell fate determinationBiologyBinding CompetitiveGeneral Biochemistry Genetics and Molecular BiologyFluorescenceProtein–protein interactionEvolution MolecularStructure-Activity Relationship[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyAnimalsShort linear motif[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyBiFCTranscription factor[SDV.BC] Life Sciences [q-bio]/Cellular BiologydevelopmentHomeodomain ProteinsABDOMINAL-AGeneral Immunology and MicrobiologyBIMOLECULAR FLUORESCENCE COMPLEMENTATIONREPRESSIONDNAPROTEIN INTERACTIONSIntrinsically Disordered ProteinsDROSOPHILA-MELANOGASTERMutationeLife
researchProduct

Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic

2004

Erythropoietin (EPO) is both hematopoietic and tissue protective, putatively through interaction with different receptors. We generated receptor subtype–selective ligands allowing the separation of EPO's bioactivities at the cellular level and in animals. Carbamylated EPO (CEPO) or certain EPO mutants did not bind to the classical EPO receptor (EPOR) and did not show any hematopoietic activity in human cell signaling assays or upon chronic dosing in different animal species. Nevertheless, CEPO and various nonhematopoietic mutants were cytoprotective in vitro and conferred neuroprotection against stroke, spinal cord compression, diabetic neuropathy, and experimental autoimmune encephalomyeli…

Encephalomyelitis Autoimmune ExperimentalEncephalomyelitiscarbamylated erythropoietinApoptosisPharmacologyLigandsNeuroprotectionRats Sprague-DawleyMiceStructure-Activity RelationshipDiabetic Neuropathiesddc:570hemic and lymphatic diseasesReceptors ErythropoietinmedicineAnimalsHumansErythropoiesisReceptorErythropoietinCells CulturedNeuronsMice Inbred C3HBinding SitesMultidisciplinaryChemistryExperimental autoimmune encephalomyelitisErythropoietin; erythropoietin receptor; carbamylated erythropoietin; neuroprotective agentsmedicine.diseaseRecombinant ProteinsRatsErythropoietin receptorStrokeNeuroprotective AgentsErythropoietin Erythropoietin derivative NeuroprotectionHematocritMutagenesisErythropoietinDrug DesignImmunologyErythropoiesisFemaleNervous System DiseasesSignal transductionerythropoietin receptorSpinal Cord CompressionSignal Transductionmedicine.drugScience
researchProduct

Endoribonuclease IV. A poly(A)-specific ribonuclease from chick oviduct. 1. Purification of the enzyme.

1976

A new endoribonuclease, termed endoribonuclease IV, has been described. This enzyme has been isolated from chick oviducts and purified 15 000-fold in a 25% yield nearly to homogeneity. The nuclease, which specifically degrades poly(A), forms oligonucleotides of an average chain length of 10. These (A)-10 fragments are terminated by 3'-hydroxyl and 5'-phosphate groups. The enzyme has a pH optimum at 8.7, requires Mn2+ or Mg2+ as a cofactor, and has a molecular weight of about 45 000.

EndoribonucleaseOviductsBiologyBiochemistryCofactorStructure-Activity RelationshipRibonucleasesAnimalsMagnesiumchemistry.chemical_classificationNucleaseManganeseOligoribonucleotidesOligonucleotideEndoribonuclease IVEndonucleasesMolecular biologyEnzyme ActivationMolecular WeightKineticsEnzymeBiochemistrychemistryYield (chemistry)biology.proteinOviductFemalePoly AChickensEuropean journal of biochemistry
researchProduct

Bioconcentration, metabolism and toxicity of substituted anilines in the zebrafish (Brachydanio rerio).

1991

The LC50 (96 h) values and the bioconcentration factors (BCF) for nine anilines (aniline; 2-, 3-, 4-chloroaniline; 2-, 3-, 4-nitroaniline; 2,4- and 3,4-dichloroaniline) in the zebrafish (Brachydanio rerio) were determined. Biotransformation products of anilines in the zebrafish were analyzed by HPLC. The aim of the investigations was to find relationships between accumulation/elimination/metabolism and toxicity on the one hand and between chemical structure and biotransformation on the other. We found a good correlation of log BCF and of log Pow with log LC50. This concurs with the assumption that the internal dose determines the toxicological effect. All anilines investigated, with the exc…

Environmental EngineeringAniline CompoundsStereochemistryBioconcentrationBiologyPollutionchemistry.chemical_compoundKineticsStructure-Activity RelationshipAnilinechemistryBiotransformationAcetylationToxicityEnvironmental ChemistryToxicokineticsStructure–activity relationshipAnimalsWaste Management and DisposalAcetanilideBiotransformationChromatography High Pressure LiquidZebrafishThe Science of the total environment
researchProduct

Chromatographic retention–activity relationships for prediction of the toxicity pH-dependence of phenols

2007

Abstract An investigation of the use of the chromatographic retention (log  k ) as an in vitro approach for modeling the pH-dependence of the toxicity to Guppy of phenols is developed. A data set of 19 phenols with available experimental toxicity–pH data was used. The importance of the mechanism of toxic action (MOA) of phenols was studied. log  k data at three pH values were used for the phenols classification and two groups or ‘MODEs’ were identified. For one ‘MODE’ a quantitative retention–activity relationship (QRAR) model was calculated. Finally, the model was used to assess the toxicity to Guppy of phenols at different pH values. The results of this investigation suggest that chromato…

Environmental EngineeringHealth Toxicology and MutagenesisQuantitative Structure-Activity RelationshipModels BiologicalLethal Dose 50chemistry.chemical_compoundPhenolsPh dependenceAnimalsEnvironmental ChemistryOrganic chemistryEcotoxicologyPhenolsChromatographyPoeciliaChromatographyChemistryPublic Health Environmental and Occupational HealthGeneral MedicineGeneral ChemistryHydrogen-Ion ConcentrationPollutionToxicityPh rangeFish <Actinopterygii>ForecastingChemosphere
researchProduct

Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor

2013

The Eph–ephrin system plays a critical role in tumor growth and vascular functions during carcinogenesis. We had previously identified cholanic acid as a competitive and reversible EphA2 antagonist able to disrupt EphA2-ephrinA1 interaction and to inhibit EphA2 activation in prostate cancer cells. Herein, we report the synthesis and biological evaluation of a set of cholanic acid derivatives obtained by conjugation of its carboxyl group with a panel of naturally occurring amino acids with the aim to improve EphA2 receptor inhibition. Structure-activity relationships indicate that conjugation of cholanic acid with linear amino acids of small size leads to effective EphA2 antagonists whereas …

EphA2 antagonistsStereochemistryStructure-activity relationship studiesPharmaceutical Sciencemedicine.disease_causeArticleProtein Structure SecondaryAnalytical Chemistrylcsh:QD241-441Inhibitory Concentration 50Structure-Activity Relationshipchemistry.chemical_compoundamino acid conjugateslcsh:Organic chemistryEphA2 anatgonistscholanic acid; amino acid conjugates; EphA2 antagonists; structure-activity relationshipsCell Line TumorDrug DiscoveryAromatic amino acidsmedicineHumansPhosphorylationPhysical and Theoretical ChemistryReceptorbile acids; EphA2 anatgonists; Structure-activity relationship studies; amino acid conjugatesbile acidschemistry.chemical_classificationBinding SitesReceptor EphA1Receptor EphA2structure-activity relationshipsOrganic ChemistryAntagonistCholic AcidsHydrogen BondingEPH receptor A2Amino acidMolecular Docking SimulationCholanic acidcholanic acidchemistryBiochemistryChemistry (miscellaneous)Molecular MedicineCarcinogenesisProtein Processing Post-TranslationalProtein BindingConjugateMolecules
researchProduct